A detailed history of Emerald Advisers, LLC transactions in Ocular Therapeutix, Inc stock. As of the latest transaction made, Emerald Advisers, LLC holds 20,768 shares of OCUL stock, worth $176,528. This represents 0.01% of its overall portfolio holdings.

Number of Shares
20,768
Previous 20,768 -0.0%
Holding current value
$176,528
Previous $142,000 26.76%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 26, 2023

SELL
$3.14 - $5.04 $78,339 - $125,742
-24,949 Reduced 54.57%
20,768 $65,000
Q1 2023

May 04, 2023

SELL
$2.79 - $6.27 $2.57 Million - $5.77 Million
-919,524 Reduced 95.26%
45,717 $240,000
Q4 2022

Feb 03, 2023

SELL
$2.61 - $4.41 $1.41 Million - $2.39 Million
-541,215 Reduced 35.93%
965,241 $2.71 Million
Q3 2022

Oct 25, 2022

BUY
$4.09 - $6.5 $166,683 - $264,901
40,754 Added 2.78%
1,506,456 $6.25 Million
Q2 2022

Jul 29, 2022

BUY
$3.01 - $5.22 $523,128 - $907,220
173,797 Added 13.45%
1,465,702 $5.89 Million
Q1 2022

Apr 29, 2022

BUY
$4.83 - $7.35 $1.13 Million - $1.72 Million
234,178 Added 22.14%
1,291,905 $6.4 Million
Q4 2021

Feb 02, 2022

BUY
$6.16 - $12.07 $1.28 Million - $2.51 Million
208,127 Added 24.5%
1,057,727 $7.37 Million
Q3 2021

Oct 28, 2021

SELL
$9.7 - $14.34 $3.63 Million - $5.36 Million
-373,900 Reduced 30.56%
849,600 $8.5 Million
Q2 2021

Jul 29, 2021

SELL
$13.43 - $19.16 $958,230 - $1.37 Million
-71,350 Reduced 5.51%
1,223,500 $17.3 Million
Q1 2021

Apr 29, 2021

BUY
$15.82 - $22.11 $1.65 Million - $2.3 Million
104,147 Added 8.75%
1,294,850 $21.2 Million
Q4 2020

Jan 29, 2021

BUY
$7.91 - $22.95 $9.42 Million - $27.3 Million
1,190,703 New
1,190,703 $24.6 Million

Others Institutions Holding OCUL

About OCULAR THERAPEUTIX, INC


  • Ticker OCUL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,966,896
  • Market Cap $654M
  • Description
  • Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...
More about OCUL
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.